CD4 and cancer: Our present study indicates that in addition to their anti-cancer effects, the two FDA-approved proteasome inhibitors, bortezomib and carfilzomib, can also synergize with existing LRAs such as JQ1 and romidepsin to reverse HIV latency in resting CD4+ T cells from ART-suppressed individuals without inducing T-cell activation or proliferation (Fig 5).